First Tracks Biotherapeutics, Inc. Ordinary Shares When-Issued (TRAXV) - Cash Flow Conversion Efficiency
Based on the latest financial reports, First Tracks Biotherapeutics, Inc. Ordinary Shares When-Issued (TRAXV) has a cash flow conversion efficiency ratio of -0.126x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-32.56 Million) by net assets ($257.46 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See net asset quality index of First Tracks Biotherapeutics, Inc. Ordin to measure how much of total assets are equity-financed.
First Tracks Biotherapeutics, Inc. Ordinary Shares When-Issued - Cash Flow Conversion Efficiency Trend (2023–2024)
This chart illustrates how First Tracks Biotherapeutics, Inc. Ordinary Shares When-Issued's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore TRAXV long-term asset investment ratio to see how much of total assets are deployed in long-term investments.
First Tracks Biotherapeutics, Inc. Ordinary Shares When-Issued Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of First Tracks Biotherapeutics, Inc. Ordinary Shares When-Issued ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Autohellas S.A.
AT:OTOEL
|
0.064x |
|
Nuveen Dynamic Municipal Opportunities Fund
NYSE:NDMO
|
N/A |
|
Nanjing CIGU Technology Corp. Ltd. A
SHG:688448
|
N/A |
|
Mah Sing Group Bhd
KLSE:8583
|
-0.035x |
|
HANA Micron Inc
KQ:067310
|
-0.039x |
|
ECOVE Environment Corp
TWO:6803
|
-0.287x |
|
Cass Information Systems Inc
NASDAQ:CASS
|
0.060x |
|
Italtile Ltd
JSE:ITE
|
0.137x |
Annual Cash Flow Conversion Efficiency for First Tracks Biotherapeutics, Inc. Ordinary Shares When-Issued (2023–2024)
The table below shows the annual cash flow conversion efficiency of First Tracks Biotherapeutics, Inc. Ordinary Shares When-Issued from 2023 to 2024. For the full company profile with market capitalisation and key ratios, see First Tracks Biotherapeutics, Inc. Ordin (TRAXV) market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $391.60 Million | $-125.81 Million | -0.321x | -41.57% |
| 2023-12-31 | $409.85 Million | $-93.00 Million | -0.227x | -- |
About First Tracks Biotherapeutics, Inc. Ordinary Shares When-Issued
First Tracks Biotherapeutics, Inc. operates as a clinical-stage biotechnology company developing antibody therapeutics that modulate immune pathways implicated in autoimmune and inflammatory diseases. First Tracks Biotherapeutics, Inc. was formerly known as Biopharma Co., Inc. and changed its name to First Tracks Biotherapeutics, Inc. in February 2026. First Tracks Biotherapeutics, Inc. was incor… Read more